



October 05, 2018

NOT SUBSTANTIALLY EQUIVALENT

Skookum Creek Tobacco Company
ATTENTION: Nathan Schreiner, Attorney
Squaxin Island Legal Department
3711 SE Old Olympic Highway
Shelton, WA 98584

FDA Submission Tracking Number (STN): SE0001889

Dear Mr. Schreiner:

The Food and Drug Administration (FDA) completed review of your Report Preceding Introduction of Certain Substantially Equivalent Products into Interstate Commerce (SE Report), submitted under section 905(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), for the following tobacco product:

New Tobacco Product

Date of Submission:	March 21, 2011
Date of Receipt:	March 22, 2011
Product Manufacturer:	Skookum Creek Tobacco Company
Product Category:	Cigarettes
Product Sub-Category:	Combusted, Filtered
Product Name:¹	Traditions, King Size, "Full Flavor"
Package Type:	Hard Pack
Package Quantity:	20 cigarettes
Length:	84 mm
Diameter:²	7.8 mm
Ventilation:	None
Characterizing flavor:	None

Based on our review of your SE Report, we find the new tobacco product specified above is not substantially equivalent to the following predicate tobacco product:

¹ Brand/sub-brand or other commercial name used in commercial distribution

² The applicant submitted the circumference which allowed for a calculation of diameter

Predicate Tobacco Product

Product Manufacturer:	Skookum Creek Tobacco Company
Product Category:	Cigarettes
Product Sub-Category:	Combusted, Filtered
Product Name:¹	Complete, King Size, "Full Flavor"
Package Type:	Hard Pack
Package Quantity:	20 cigarettes
Length:	84 mm
Diameter:²	7.8 mm
Ventilation:	None
Characterizing flavor:	None
Eligibility Type:	Grandfathered

We have described below our basis for this determination.

1. Your SE Report indicates that the smoke yields of NNN (29% increase under ISO and 37% increase under CI) and NNK (98% increase under ISO and 137% increase under CI) are significantly increased in the mainstream smoke of the new tobacco product compared to the predicate tobacco product. NNN and NNK are carcinogenic to humans. However, your SE Report does not provide adequate scientific evidence and rationale that the increases in NNN and NNK yields do not cause the new tobacco product to raise different questions of public health.

You did not provide sufficient information to support a finding of substantial equivalence; therefore, we are issuing an order finding that this new tobacco product is not substantially equivalent to an appropriate predicate tobacco product. Upon issuance of this order, your tobacco product is misbranded under section 903(a)(6) of the FD&C Act and adulterated under section 902(6)(A) of the FD&C Act. Failure to comply with the FD&C Act may result in FDA taking regulatory action without further notice. These actions may include, but are not limited to, civil money penalties, seizure, and/or injunction.

Additionally, FDA requests that within 15 days of this letter you submit a plan detailing the steps you plan to take to ensure that this misbranded and adulterated product is not further distributed, imported, sold, marketed, or promoted in the United States by others. Your plan should include information sufficient to distinguish this misbranded and adulterated product from legally marketed tobacco products, including, but not limited to lot numbers, manufacturing codes, and manufacturing dates. The plan should also include a list of your direct accounts and contain their contact information. Submit your plan to the address below with a cover letter that includes the following text in the subject line:

COMPLIANCE PLAN for SE0001889

FDA will post product identifying information on a list of tobacco products that are adulterated and misbranded due to an NSE order, available to the public at

<https://www.fda.gov/TobaccoProducts/Labeling/TobaccoProductReviewEvaluation/ucm371765.htm>

We remind you that you are required to update your listing information in June and December of each year under section 905(i)(3) of the FD&C Act. As part of this listing update, under section 905(i)(3)(B) of the FD&C Act, you must provide information on the date of discontinuance and product identity for any product you discontinue.

If you wish to request supervisory review of this decision under 21 CFR 10.75, please submit the request via the CTP Portal

(<http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/Manufacturing/ucm515047.htm>)³ using eSubmitter (<http://www.fda.gov/ForIndustry/FDAeSubmitter>), or mail it to:

Food and Drug Administration
Center for Tobacco Products
Document Control Center (DCC)
Building 71, Room G335
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002

The CTP Portal and FDA Electronic Submission Gateway (ESG) are generally available 24 hours a day, seven days a week; if the upload is successful, submissions are considered received by DCC on the day of upload. Submissions delivered to DCC by courier or physical mail will be considered timely if received during delivery hours on or before the due date (see <http://www.fda.gov/tobaccoproducts/aboutctp/contactus/default.htm>); if the due date falls on a weekend or holiday the delivery must be received on or before the preceding business day. We are unable to accept regulatory submissions by e-mail.

We ask that your request be sent as a single submission with a cover letter that includes the following text in your subject line: **REQUEST FOR SUPERVISORY REVIEW for SE0001889**. In addition, we ask you to identify each basis for the request and include all information on which you wish your request to be based; it may not contain any new data or analysis that was not part of your SE Report.

To legally market the new product described in this application, it must comply with the requirements in section 910(a)(2)(A) of the FD&C Act.

See the following website for additional information on these three pathways:

<https://www.fda.gov/TobaccoProducts/Labeling/TobaccoProductReviewEvaluation/default.htm>

If you have any questions, please contact Barbara Banchemo, Regulatory Health Project Manager, at (301) 796-1937 or Barbara.Banchemo@fda.hhs.gov.

Sincerely,

Digitally signed by Matthew R. Holman -S

Date: 2018.10.05 12:06:12 -04'00'

Matthew R. Holman, Ph.D.

Director

Office of Science

Center for Tobacco Products

³ The FDA's Electronic Submission Gateway (ESG) is still available as an alternative to the CTP Portal.